Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML‐RARα isoforms: a study of the PETHEMA group
Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)‐form (50%), eight variable (V)‐form (5%) and 76 short (S)‐form (45%). The V‐form and S‐form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 109/l (P ...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2001-07, Vol.114 (1), p.99-103 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103 |
|---|---|
| container_issue | 1 |
| container_start_page | 99 |
| container_title | British journal of haematology |
| container_volume | 114 |
| creator | González, M. Barragán, E. Bolufer, P. Chillón, C. Colomer, D. Borstein, R. Calasanz, M. J. Gómez‐Casares, M. T. Villegas, A. Marugán, I. Román, J. Martín, G. Rayón, C. Debén, G. Tormo, M. Díaz‐Mediavilla, J. Esteve, J. González‐San Miguel, J. Rivas, C. Pérez‐Equiza, K. García‐Sanz, R. Capote, F. J. Ribera, J. M. Arias, J. León, A. Sanz, M. A. |
| description | Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)‐form (50%), eight variable (V)‐form (5%) and 76 short (S)‐form (45%). The V‐form and S‐form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 109/l (P |
| doi_str_mv | 10.1046/j.1365-2141.2001.02915.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71036971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71036971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4455-615b16cbc55175130cb656399204e5344a956555f8952543aa644f0fb094c7193</originalsourceid><addsrcrecordid>eNqNkUFu1DAUhi0EokPLFZA3sEuwEz9njMRiqAaGaiqqqqwtx-O0HpJ4sB3R7DgCN-AMXIRDcJI6nRHddmVL_v7ffv4QwpTklDD-dpvTkkNWUEbzghCak0JQyG-foNn_g6doRgipshSYH6EXIWwTWBKgz9ERpawqSqAz9PvCm-iNip3pI9Y3yisdjbchWh2w6jdYt7a3WrXYDVG7zmDXYKWHaPDOu240rdNjgnFrhm_KdFbhnYo2taW41s5vbH-No8PxxuCL8_W_n78uF5d__2AbXON8F95hhUMcNuNUfA8tr1bL8wW-9m7YnaBnjWqDeXlYj9HXj8ur01W2_vLp8-linWnGADJOoaZc1xqAVpDG1DUHXgpREGagZEwJ4ADQzAUUwEqlOGMNaWoimK6oKI_Rm31vGur7YEKUnQ3atK3qjRuCrCgpuahoAud7UHsXgjeN3HnbKT9KSuQkR27l5EBODuQkR97Lkbcp-upwx1B3ZvMQPNhIwOsDoEL68carXtvwwDHCQVQ8ce_33A_bmvHRD5AfzlbTrrwDSmysnw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71036971</pqid></control><display><type>article</type><title>Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML‐RARα isoforms: a study of the PETHEMA group</title><source>MEDLINE</source><source>Wiley Online Library</source><source>Free E-Journal (出版社公開部分のみ）</source><creator>González, M. ; Barragán, E. ; Bolufer, P. ; Chillón, C. ; Colomer, D. ; Borstein, R. ; Calasanz, M. J. ; Gómez‐Casares, M. T. ; Villegas, A. ; Marugán, I. ; Román, J. ; Martín, G. ; Rayón, C. ; Debén, G. ; Tormo, M. ; Díaz‐Mediavilla, J. ; Esteve, J. ; González‐San Miguel, J. ; Rivas, C. ; Pérez‐Equiza, K. ; García‐Sanz, R. ; Capote, F. J. ; Ribera, J. M. ; Arias, J. ; León, A. ; Sanz, M. A.</creator><creatorcontrib>González, M. ; Barragán, E. ; Bolufer, P. ; Chillón, C. ; Colomer, D. ; Borstein, R. ; Calasanz, M. J. ; Gómez‐Casares, M. T. ; Villegas, A. ; Marugán, I. ; Román, J. ; Martín, G. ; Rayón, C. ; Debén, G. ; Tormo, M. ; Díaz‐Mediavilla, J. ; Esteve, J. ; González‐San Miguel, J. ; Rivas, C. ; Pérez‐Equiza, K. ; García‐Sanz, R. ; Capote, F. J. ; Ribera, J. M. ; Arias, J. ; León, A. ; Sanz, M. A. ; Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group ; for the Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group</creatorcontrib><description>Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)‐form (50%), eight variable (V)‐form (5%) and 76 short (S)‐form (45%). The V‐form and S‐form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 109/l (P < 0·05). The S‐form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0·005) and CD34 expression (P < 0·0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3‐year disease‐free survival was lower for V‐form cases than it was for L‐ and S‐form cases (62% vs. 94% and 89%, P = 0·056). We conclude that the V‐form and S‐form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V‐form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1046/j.1365-2141.2001.02915.x</identifier><identifier>PMID: 11472351</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>acute promyelocytic leukaemia ; Adolescent ; Adult ; Aged ; all‐trans retinoic acid (ATRA) ; Antigens, CD34 - analysis ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; clinical outcome ; complete remission ; Disease-Free Survival ; Female ; Hematologic and hematopoietic diseases ; Humans ; Infant ; Infant, Newborn ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukemia, Promyelocytic, Acute - immunology ; Leukemia, Promyelocytic, Acute - metabolism ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Leukocyte Count ; Male ; Medical sciences ; Middle Aged ; Neoplasm Proteins - genetics ; Oncogene Proteins, Fusion - genetics ; PML/RARα isoform ; Polymerase Chain Reaction - methods ; Prognosis ; Proportional Hazards Models ; Protein Isoforms - genetics ; reverse transcription–polymerase chain reaction (RT–PCR) ; Treatment Outcome ; Tretinoin - therapeutic use</subject><ispartof>British journal of haematology, 2001-07, Vol.114 (1), p.99-103</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4455-615b16cbc55175130cb656399204e5344a956555f8952543aa644f0fb094c7193</citedby><cites>FETCH-LOGICAL-c4455-615b16cbc55175130cb656399204e5344a956555f8952543aa644f0fb094c7193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2141.2001.02915.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2141.2001.02915.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14065976$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11472351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>González, M.</creatorcontrib><creatorcontrib>Barragán, E.</creatorcontrib><creatorcontrib>Bolufer, P.</creatorcontrib><creatorcontrib>Chillón, C.</creatorcontrib><creatorcontrib>Colomer, D.</creatorcontrib><creatorcontrib>Borstein, R.</creatorcontrib><creatorcontrib>Calasanz, M. J.</creatorcontrib><creatorcontrib>Gómez‐Casares, M. T.</creatorcontrib><creatorcontrib>Villegas, A.</creatorcontrib><creatorcontrib>Marugán, I.</creatorcontrib><creatorcontrib>Román, J.</creatorcontrib><creatorcontrib>Martín, G.</creatorcontrib><creatorcontrib>Rayón, C.</creatorcontrib><creatorcontrib>Debén, G.</creatorcontrib><creatorcontrib>Tormo, M.</creatorcontrib><creatorcontrib>Díaz‐Mediavilla, J.</creatorcontrib><creatorcontrib>Esteve, J.</creatorcontrib><creatorcontrib>González‐San Miguel, J.</creatorcontrib><creatorcontrib>Rivas, C.</creatorcontrib><creatorcontrib>Pérez‐Equiza, K.</creatorcontrib><creatorcontrib>García‐Sanz, R.</creatorcontrib><creatorcontrib>Capote, F. J.</creatorcontrib><creatorcontrib>Ribera, J. M.</creatorcontrib><creatorcontrib>Arias, J.</creatorcontrib><creatorcontrib>León, A.</creatorcontrib><creatorcontrib>Sanz, M. A.</creatorcontrib><creatorcontrib>Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group</creatorcontrib><creatorcontrib>for the Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group</creatorcontrib><title>Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML‐RARα isoforms: a study of the PETHEMA group</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)‐form (50%), eight variable (V)‐form (5%) and 76 short (S)‐form (45%). The V‐form and S‐form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 109/l (P < 0·05). The S‐form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0·005) and CD34 expression (P < 0·0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3‐year disease‐free survival was lower for V‐form cases than it was for L‐ and S‐form cases (62% vs. 94% and 89%, P = 0·056). We conclude that the V‐form and S‐form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V‐form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.</description><subject>acute promyelocytic leukaemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>all‐trans retinoic acid (ATRA)</subject><subject>Antigens, CD34 - analysis</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>clinical outcome</subject><subject>complete remission</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukemia, Promyelocytic, Acute - immunology</subject><subject>Leukemia, Promyelocytic, Acute - metabolism</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - genetics</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>PML/RARα isoform</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Protein Isoforms - genetics</subject><subject>reverse transcription–polymerase chain reaction (RT–PCR)</subject><subject>Treatment Outcome</subject><subject>Tretinoin - therapeutic use</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFu1DAUhi0EokPLFZA3sEuwEz9njMRiqAaGaiqqqqwtx-O0HpJ4sB3R7DgCN-AMXIRDcJI6nRHddmVL_v7ffv4QwpTklDD-dpvTkkNWUEbzghCak0JQyG-foNn_g6doRgipshSYH6EXIWwTWBKgz9ERpawqSqAz9PvCm-iNip3pI9Y3yisdjbchWh2w6jdYt7a3WrXYDVG7zmDXYKWHaPDOu240rdNjgnFrhm_KdFbhnYo2taW41s5vbH-No8PxxuCL8_W_n78uF5d__2AbXON8F95hhUMcNuNUfA8tr1bL8wW-9m7YnaBnjWqDeXlYj9HXj8ur01W2_vLp8-linWnGADJOoaZc1xqAVpDG1DUHXgpREGagZEwJ4ADQzAUUwEqlOGMNaWoimK6oKI_Rm31vGur7YEKUnQ3atK3qjRuCrCgpuahoAud7UHsXgjeN3HnbKT9KSuQkR27l5EBODuQkR97Lkbcp-upwx1B3ZvMQPNhIwOsDoEL68carXtvwwDHCQVQ8ce_33A_bmvHRD5AfzlbTrrwDSmysnw</recordid><startdate>200107</startdate><enddate>200107</enddate><creator>González, M.</creator><creator>Barragán, E.</creator><creator>Bolufer, P.</creator><creator>Chillón, C.</creator><creator>Colomer, D.</creator><creator>Borstein, R.</creator><creator>Calasanz, M. J.</creator><creator>Gómez‐Casares, M. T.</creator><creator>Villegas, A.</creator><creator>Marugán, I.</creator><creator>Román, J.</creator><creator>Martín, G.</creator><creator>Rayón, C.</creator><creator>Debén, G.</creator><creator>Tormo, M.</creator><creator>Díaz‐Mediavilla, J.</creator><creator>Esteve, J.</creator><creator>González‐San Miguel, J.</creator><creator>Rivas, C.</creator><creator>Pérez‐Equiza, K.</creator><creator>García‐Sanz, R.</creator><creator>Capote, F. J.</creator><creator>Ribera, J. M.</creator><creator>Arias, J.</creator><creator>León, A.</creator><creator>Sanz, M. A.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200107</creationdate><title>Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML‐RARα isoforms: a study of the PETHEMA group</title><author>González, M. ; Barragán, E. ; Bolufer, P. ; Chillón, C. ; Colomer, D. ; Borstein, R. ; Calasanz, M. J. ; Gómez‐Casares, M. T. ; Villegas, A. ; Marugán, I. ; Román, J. ; Martín, G. ; Rayón, C. ; Debén, G. ; Tormo, M. ; Díaz‐Mediavilla, J. ; Esteve, J. ; González‐San Miguel, J. ; Rivas, C. ; Pérez‐Equiza, K. ; García‐Sanz, R. ; Capote, F. J. ; Ribera, J. M. ; Arias, J. ; León, A. ; Sanz, M. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4455-615b16cbc55175130cb656399204e5344a956555f8952543aa644f0fb094c7193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>acute promyelocytic leukaemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>all‐trans retinoic acid (ATRA)</topic><topic>Antigens, CD34 - analysis</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>clinical outcome</topic><topic>complete remission</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukemia, Promyelocytic, Acute - immunology</topic><topic>Leukemia, Promyelocytic, Acute - metabolism</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - genetics</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>PML/RARα isoform</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Protein Isoforms - genetics</topic><topic>reverse transcription–polymerase chain reaction (RT–PCR)</topic><topic>Treatment Outcome</topic><topic>Tretinoin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>González, M.</creatorcontrib><creatorcontrib>Barragán, E.</creatorcontrib><creatorcontrib>Bolufer, P.</creatorcontrib><creatorcontrib>Chillón, C.</creatorcontrib><creatorcontrib>Colomer, D.</creatorcontrib><creatorcontrib>Borstein, R.</creatorcontrib><creatorcontrib>Calasanz, M. J.</creatorcontrib><creatorcontrib>Gómez‐Casares, M. T.</creatorcontrib><creatorcontrib>Villegas, A.</creatorcontrib><creatorcontrib>Marugán, I.</creatorcontrib><creatorcontrib>Román, J.</creatorcontrib><creatorcontrib>Martín, G.</creatorcontrib><creatorcontrib>Rayón, C.</creatorcontrib><creatorcontrib>Debén, G.</creatorcontrib><creatorcontrib>Tormo, M.</creatorcontrib><creatorcontrib>Díaz‐Mediavilla, J.</creatorcontrib><creatorcontrib>Esteve, J.</creatorcontrib><creatorcontrib>González‐San Miguel, J.</creatorcontrib><creatorcontrib>Rivas, C.</creatorcontrib><creatorcontrib>Pérez‐Equiza, K.</creatorcontrib><creatorcontrib>García‐Sanz, R.</creatorcontrib><creatorcontrib>Capote, F. J.</creatorcontrib><creatorcontrib>Ribera, J. M.</creatorcontrib><creatorcontrib>Arias, J.</creatorcontrib><creatorcontrib>León, A.</creatorcontrib><creatorcontrib>Sanz, M. A.</creatorcontrib><creatorcontrib>Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group</creatorcontrib><creatorcontrib>for the Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>González, M.</au><au>Barragán, E.</au><au>Bolufer, P.</au><au>Chillón, C.</au><au>Colomer, D.</au><au>Borstein, R.</au><au>Calasanz, M. J.</au><au>Gómez‐Casares, M. T.</au><au>Villegas, A.</au><au>Marugán, I.</au><au>Román, J.</au><au>Martín, G.</au><au>Rayón, C.</au><au>Debén, G.</au><au>Tormo, M.</au><au>Díaz‐Mediavilla, J.</au><au>Esteve, J.</au><au>González‐San Miguel, J.</au><au>Rivas, C.</au><au>Pérez‐Equiza, K.</au><au>García‐Sanz, R.</au><au>Capote, F. J.</au><au>Ribera, J. M.</au><au>Arias, J.</au><au>León, A.</au><au>Sanz, M. A.</au><aucorp>Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group</aucorp><aucorp>for the Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML‐RARα isoforms: a study of the PETHEMA group</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2001-07</date><risdate>2001</risdate><volume>114</volume><issue>1</issue><spage>99</spage><epage>103</epage><pages>99-103</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)‐form (50%), eight variable (V)‐form (5%) and 76 short (S)‐form (45%). The V‐form and S‐form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 109/l (P < 0·05). The S‐form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0·005) and CD34 expression (P < 0·0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3‐year disease‐free survival was lower for V‐form cases than it was for L‐ and S‐form cases (62% vs. 94% and 89%, P = 0·056). We conclude that the V‐form and S‐form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V‐form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11472351</pmid><doi>10.1046/j.1365-2141.2001.02915.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2001-07, Vol.114 (1), p.99-103 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71036971 |
| source | MEDLINE; Wiley Online Library; Free E-Journal (出版社公開部分のみ） |
| subjects | acute promyelocytic leukaemia Adolescent Adult Aged all‐trans retinoic acid (ATRA) Antigens, CD34 - analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Child Child, Preschool clinical outcome complete remission Disease-Free Survival Female Hematologic and hematopoietic diseases Humans Infant Infant, Newborn Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - immunology Leukemia, Promyelocytic, Acute - metabolism Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocyte Count Male Medical sciences Middle Aged Neoplasm Proteins - genetics Oncogene Proteins, Fusion - genetics PML/RARα isoform Polymerase Chain Reaction - methods Prognosis Proportional Hazards Models Protein Isoforms - genetics reverse transcription–polymerase chain reaction (RT–PCR) Treatment Outcome Tretinoin - therapeutic use |
| title | Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML‐RARα isoforms: a study of the PETHEMA group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A21%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20characteristics%20and%20clinical%20outcome%20of%20acute%20promyelocytic%20leukaemia%20patients%20according%20to%20the%20PML%E2%80%90RAR%CE%B1%20isoforms:%20a%20study%20of%20the%20PETHEMA%20group&rft.jtitle=British%20journal%20of%20haematology&rft.au=Gonz%C3%A1lez,%20M.&rft.aucorp=Spanish%20Programme%20for%20the%20Study%20and%20Treatment%20of%20Haematological%20Malignancies%20(PETHEMA)%20Group&rft.date=2001-07&rft.volume=114&rft.issue=1&rft.spage=99&rft.epage=103&rft.pages=99-103&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1046/j.1365-2141.2001.02915.x&rft_dat=%3Cproquest_cross%3E71036971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71036971&rft_id=info:pmid/11472351&rfr_iscdi=true |